KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Change in Cash (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Change in Cash for 17 consecutive years, with $61.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Cash fell 76.97% year-over-year to $61.6 million, compared with a TTM value of $368.8 million through Dec 2025, up 96.49%, and an annual FY2025 reading of $368.8 million, up 96.49% over the prior year.
  • Change in Cash was $61.6 million for Q4 2025 at Biomarin Pharmaceutical, up from $36.3 million in the prior quarter.
  • Across five years, Change in Cash topped out at $267.4 million in Q4 2024 and bottomed at -$296.7 million in Q3 2024.
  • Average Change in Cash over 5 years is $33.1 million, with a median of $18.2 million recorded in 2021.
  • The sharpest move saw Change in Cash plummeted 895.29% in 2023, then surged 1403.17% in 2025.
  • Year by year, Change in Cash stood at -$29.9 million in 2021, then fell by 23.83% to -$37.0 million in 2022, then grew by 18.11% to -$30.3 million in 2023, then soared by 982.87% to $267.4 million in 2024, then crashed by 76.97% to $61.6 million in 2025.
  • Business Quant data shows Change in Cash for BMRN at $61.6 million in Q4 2025, $36.3 million in Q3 2025, and $165.0 million in Q2 2025.